IPSEN (OTCMKTS:IPSEY) Shares Up 7.5% – Still a Buy?

IPSEN (OTCMKTS:IPSEY)’s stock price traded up 7.5% during trading on Friday . The company traded as high as $48.1850 and last traded at $48.1850. Approximately 169 shares changed hands during trading, a decline of 92% from the average daily volume of 2,113 shares. The stock had previously closed at $44.81.

Wall Street Analyst Weigh In

A number of analysts have issued reports on IPSEY shares. HC Wainwright reissued a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Zacks Research raised shares of IPSEN to a “hold” rating in a report on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, IPSEN currently has an average rating of “Hold”.

IPSEN Trading Up 6.9%

The firm has a fifty day moving average price of $45.89 and a 200-day moving average price of $45.49.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).